Personalized melanoma vaccine cuts recurrence or death by 42%

· Science

An international phase 3 trial found that adding intismeran — a personalized therapeutic cancer vaccine made from each patient's own tumor — to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results reported by Medical Xpress and Nature News. Nature News describes the mRNA-based vaccine as almost halving the risk of skin cancer returning. The approach belongs to a growing class of tailored cancer vaccines designed around the mutations in an individual patient's tumor, paired with checkpoint-inhibitor drugs that help the immune system attack cancer cells. The result is among the clearest clinical signals yet for personalized cancer vaccines, a field that has drawn heavy investment from mRNA vaccine makers. It points toward a post-surgical treatment path in which a vaccine is matched to each patient's tumor to lower the chance the cancer comes back.

Why it matters：A large recurrence-risk reduction for a personalized vaccine validates the tumor-tailored mRNA approach and could accelerate investment and approval paths for similar cancer vaccines.

Key points

  • The vaccine is made from each patient's own tumor and given with pembrolizumab after surgery.
  • The trial was described as a world-first international study in high-risk melanoma.
  • The result concerns therapeutic vaccines, a step beyond preventive mRNA shots.

Sources (original reporting)

More stories from this day